

Overview of Public Meeting & Day 1 Roadmap

Judy Staffa, Ph.D., R.Ph. Associate Director for Public Health Initiatives Office of Surveillance & Epidemiology Center for Drug Evaluation and Research US Food and Drug Administration




Rationale for this scientific workshop

- What is the impetus for today's meeting?
- Why did we invite you here today?
- How will the meeting work?
- What do we envision as the output?



What is the impetus for today's meeting?

Nationally Estimated Number of Prescriptions Dispensed for Opioid Analgesics* Products from U.S. Outpatient Retail Pharmacies



Nationally Estimates of Prescriptions Dispensed for Opioid Analgesics from U.S. Outpatient Retail Pharmacies


Source: National Prescription Audit (NPA) and static data 2006-2011. January 2006-December 2016 Extracted March 2017. * Immediate-Release formulations included oral solids, oral liquids, rectal, nasal, and transmucosal products. ** Extended-Release/Long-Acting formulations included oral solids and transdermal patches. Note: Included opioid analgesics only. Excluded injectable products, cough-cold

www.fda.gov

products, and Medication-Assisted Treatment (MAT) products

FDA

FDA





FDA Opioids Action Plan

- Expand the use of advisory committees
- Develop warnings and safety information for immediaterelease (IR) opioid labeling
- Strengthen postmarket requirements to get needed data
- Update Risk Evaluation and Mitigation Strategy (REMS) Program for Prescription Opioids
- Expand access to abuse-deterrent formulations (ADFs) to discourage abuse
- Support better treatment for prescription opioid abuse and overdose
- Reassess the risk-benefit approval framework for opioid use

--www.fda.gov/NewsEvents/Newsroom/FactSheets/ucm484714.htm

Abuse-Deterrent Opioids — Evaluation and Labeling

Guidance for Industry

Additional copies are available from: Office of Communications Division of Drug Information, WO51, Room 2201 10903 New Hampshire Ave. Silver Spring, MD 20993-0002 Phone: 301-796-3400; Fax: 301-847-8714 druginfo@fda.hhs.gov http://www.fda.gov/Drugz/GuidancecOmplianceRegulatoryInformation/Guidancec/default.htm

> U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

> > Clinical Medical April 2015



Terminology

- "Abuse deterrent formulations"
 - Are not "abuse proof"
 - Are designed to deter <u>specific</u> routes of abuse (e.g. intranasal, injection)
 - Are not designed to prevent addiction
 - Have properties intended to deter abuse, as demonstrated in pre-market assessments
 - In vitro studies
 - Human abuse potential (HAP) studies
- For brevity, we will refer to such formulations as "ADFs" throughout our talks

Products with approved abusedeterrent labeling




 Based on *in vitro* and *in vivo* premarket data, ten opioid products labeled as having properties *expected to deter abuse:*

> OxyContin Targiniq ER Embeda Hysingla ER MorphaBond

Xtampza ER Troxyca ER Arymo ER Vantrela ER Roxybond *(first IR)*

 All have postmarket requirements (PMRs) to evaluate the impact of these properties on abuse in the "real-world" post-approval setting

Nationally Estimated Number of Prescriptions Dispensed for Opioid Analgesic Products^{*} <u>with abuse deterrent properties</u> from U.S. Outpatient Retail Pharmacies



Source: QuintilesIMS National Prescription Audit[™], Years 2009-2016. Data Extracted March 2017. *Not marketed during study period: Targiniq (oxycodone/naloxone ER) - Approved 07/2014; MorphaBond (morphine ER) - Approved 10/2015; Troxyca (oxycodone/naltrexone ER) - Approved 08/2016 – Roxybond (oxycodone IR) – Approved 04/2017 Goal of Postmarket Evaluation of Opioids with Abuse-deterrent Properties *(from FDA Guidance for Industry)*



"Goal of postmarket studies is to determine whether the marketing of a product with abuse-deterrent properties results in **meaningful reductions** in abuse, misuse and related adverse clinical outcomes, including addiction, overdose, and death in the postapproval setting...Given the changing landscape, a numerical threshold cannot define what would be consider a meaningful reduction."

1. "Abuse-Deterrent Opioids—Evaluation and Labeling: Guidance for Industry," FDA Center for Drug Evaluation and Research, April 2015 Postmarket Evaluation of Opioids with Abuse-deterrent Properties (from FDA Guidance for Industry)

Formal studies

- Hypothesis-driven
- Meaningful measures of abuse (including route) and related adverse outcomes
- National or multiple large geographic regions
- Sufficiently powered to examine trends

• Supportive information

- Can be qualitative, descriptive, smaller
- Provide context, aid interpretation of formal studies

Postmarket Evaluation of Opioids with FDA Abuse-deterrent Properties

• Recently moved to 2-phase approach:

Phase 1: Descriptive and feasibility

Provide surveillance data on utilization, scope, and patterns of abuse



Phase 2: Hypothesis Testing

Once market uptake is sufficient, conduct studies to evaluate for meaningful reduction in abuse and related outcomes

Postmarket Abuse-deterrent Labeling

- Labeling dictates how a product can be legally marketed
- Claims in drug labels require
 - High quality studies (but here we don't have RCTs!)
 - In-depth FDA review
 - Often, public discussion and outside expert input
- Goal is to provide informative and scientifically accurate information
- Currently, no opioid product label states that it reduces abuse in the community (Category 4 labeling) – only that it is "expected" to do so, based on pre-market evaluations



Challenges




How is abuse different from traditional pharmacoepidemiology safety outcomes?

- Abuse and related outcomes occur in patients and non-patients
- Traditional data sources (claims/EMR) are specific to patients under medical care
- Abuse is covert behavior—not captured well in these sources
- Outcomes associated with drug abuse are social/legal, as well as medical—manifest in multiple settings

Pathways to Abuse/Misuse of Prescription Drugs and Related Adverse Outcomes

FDA





Challenges with Current Postmarketing Data used to Evaluate Abuse-Deterrence

- Most studies use ecologic time series design: prepost comparison of abuse rates
- Goal is to isolate effect of abuse-deterrent formulation, support causal inference
- Must minimize other changes over time that could bias/confound pre-post comparison

Challenges with Current Postmarketing Data used to Evaluate Abuse-Deterrence

- No nationally-representative data that can reliably estimate national abuse, addiction, overdose rates for specific opioid products – by route
- Attempt "mosaic approach," looking for consistency in multiple imperfect data sources
- Currently available data sources have significant limitations that can bias pre-post comparisons over time



Why did we invite you here today?

- It's time for an open discussion around the <u>scientific issues</u>, rather than around specific products
- Invited a diverse group of scientists outside of FDA who are knowledgeable about:
 - Studying drug abuse, using currently available data (licit or illicit drugs)
 - Conducting surveillance on/building data systems to study other public health problems at a national level
 - Possibly relevant data sources NOT used widely to study prescription drug abuse
 - Survey design methodology/projection science
 - The scientific rigor needed for regulatory decision-making (us)
- Our goal: draw various areas of expertise into 1 conversation to brainstorm solutions to the current challenges



How will the meeting work?



Overall Roadmap

• **Day 1**: Focused on improving the use of existing data sources

• **Day 2**: Focused on development and use of new data sources and capabilities

Day 1 Sessions: Improving the use of existing data sources



- Session 1 Data resources used to investigate drug products with properties intended to deter abuse
- Session 2 Sampling, metrics and denominators
- Session 3 Causality and control for confounding
- Session 4 Strategies to overcome/mitigate some of the identified challenges

Day 2 Sessions: Use and development of new sources and capabilities

- Session 5 National surveys: Opportunities for Evaluation of ADFs
- **Session 6** Designs That Assess Exposure and Outcome in the Same Individuals Over Time
- Session 7 Leveraging other data: Linking and Benchmarking
- Session 8 Next steps



Format for each session

- FDA epidemiologist and statistician will present brief overview of the issues (15 min) and discussion questions
- They will moderate group discussion (60 min)
- Opportunity for **brief** audience comments (15 min)
 - Please focus comments on the topic of the session
 - Not an FDA Advisory Committee
- Opportunity for detailed comments to be submitted to docket – open till 9/11/17 - Docket Number is FDA-2017-N-2903
- <u>https://www.fda.gov/Drugs/NewsEvents/ucm540845.ht</u>
 <u>m</u>



What do we envision as the output?

Path Forward - immediate



- FDA continues to support development of effective abuse-deterrent opioid products and rigorous evaluation of their impact -- just one part of multipronged effort to address opioid crisis
- Continue to work with drug manufacturers through PMRs to improve postmarket studies – publicly share results
- Use what we learn in this meeting to inform our conversations with industry and update our guidance

Path Forward - intermediate



- FDA contracted access to poison control center and treatment center data in 2016
 - AAPCC, RADARS treatment centers, NAVIPPRO
- Working with other federal agencies to develop new data resources and enhance existing ones
 - NCHS/SAMHSA National Hospital Care Survey ("new DAWN")
 - CDC NEISS/CADES adding in abuse-related cases
 - NCHS/Vital Statistics Extraction of specific drugs from literal text on death certificates
- Collaborative project Yale-Mayo Center for Excellence in Regulatory Science Innovation (CERSI) grant
 - Linking disparate data sources together across CT to study fatal and nonfatal opioid overdoses



Path Forward – long term

- Broad Agency Announcement (BAA) issued in 2016, soliciting research proposals in this area for possible FDA funding
- Ideas can also be shared with a new working group in HHS that is interested in stakeholder ideas about ways to build data infrastructure to study opioid abuse.

